Literature DB >> 19051075

Circulating microparticles and endogenous estrogen in newly menopausal women.

M Jayachandran1, R D Litwiller, W G Owen, V M Miller.   

Abstract

BACKGROUND: Estrogen modulates antithrombotic characteristics of the vascular endothelium and the interaction of blood elements with the vascular surface. A marker of these modulatory activities is formation of cell-specific microparticles. This study examined the relationship between blood-borne microparticles and endogenous estrogen at menopause.
METHODS: Platelet activation and plasma microparticles were characterized from women being screened (n = 146) for the Kronos Early Estrogen Prevention Study. Women were grouped according to serum estrogen (< 20 pg/ml; low estrogen, n = 21 or > 40 pg/ml; high estrogen, n = 11).
RESULTS: Age, body mass index, blood pressure and blood chemistries were the same in both groups. No woman was hypertensive, diabetic or a current smoker. Platelet counts, basal and activated expression of P-selectin on platelet membranes were the same, but activated expression of glycoprotein IIb/IIIa was greater in the high-estrogen group. Numbers of endothelium-, platelet-, monocyte- and granulocyte-derived microparticles were greater in the low-estrogen group. Of the total numbers of microparticles, those positive for phosphatidylserine and tissue factor were also greater in the low-estrogen group.
CONCLUSION: These results suggest that, with declines in endogenous estrogen at menopause, numbers of procoagulant microparticles increase and thus may provide a means to explore mechanisms for cardiovascular risk development in newly menopausal women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19051075      PMCID: PMC3018155          DOI: 10.1080/13697130802488607

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  37 in total

1.  Cellular origin and procoagulant properties of microparticles in meningococcal sepsis.

Authors:  R Nieuwland; R J Berckmans; S McGregor; A N Böing; F P Romijn; R G Westendorp; C E Hack; A Sturk
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

2.  Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women.

Authors:  R C Christian; S Harrington; W D Edwards; A L Oberg; L A Fitzpatrick
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

3.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Authors:  H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen
Journal:  Ann Intern Med       Date:  2001-12-04       Impact factor: 25.391

4.  Comparison of estrogen and androgen levels after oral estrogen replacement therapy.

Authors:  C C Slater; C Zhang; H N Hodis; W J Mack; R Boostanfar; D Shoupe; R J Paulson; F Z Stanczyk
Journal:  J Reprod Med       Date:  2001-12       Impact factor: 0.142

5.  Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women.

Authors:  Muthuvel Jayachandran; Robert D Litwiller; Whyte G Owen; John A Heit; Thomas Behrenbeck; Sharon L Mulvagh; Philip A Araoz; Matthew J Budoff; S Mitchell Harman; Virginia M Miller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-11       Impact factor: 4.733

6.  Platelet characteristics associated with coronary artery disease.

Authors:  R D McBane; K Karnicki; N Tahirkheli; R S Miller; W G Owen
Journal:  J Thromb Haemost       Date:  2003-06       Impact factor: 5.824

7.  Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets.

Authors:  Ingrid Müller; Antje Klocke; Meike Alex; Matthias Kotzsch; Thomas Luther; Eberhard Morgenstern; Susanne Zieseniss; Stefan Zahler; Klaus Preissner; Bernd Engelmann
Journal:  FASEB J       Date:  2003-01-02       Impact factor: 5.191

8.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.

Authors:  Aruna D Pradhan; JoAnn E Manson; Jacques E Rossouw; David S Siscovick; Charles P Mouton; Nader Rifai; Robert B Wallace; Rebecca D Jackson; Mary B Pettinger; Paul M Ridker
Journal:  JAMA       Date:  2002-08-28       Impact factor: 56.272

9.  Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.

Authors:  Arun S Shet; Omer Aras; Kalpna Gupta; Mathew J Hass; Douglas J Rausch; Nabil Saba; Louann Koopmeiners; Nigel S Key; Robert P Hebbel
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

Review 10.  Microparticles in cardiovascular diseases.

Authors:  Marja J VanWijk; E VanBavel; A Sturk; R Nieuwland
Journal:  Cardiovasc Res       Date:  2003-08-01       Impact factor: 10.787

View more
  23 in total

1.  Methodology for isolation, identification and characterization of microvesicles in peripheral blood.

Authors:  Muthuvel Jayachandran; Virginia M Miller; John A Heit; Whyte G Owen
Journal:  J Immunol Methods       Date:  2011-10-29       Impact factor: 2.303

2.  Specific cell-derived microvesicles: Linking endothelial function to carotid artery intima-media thickness in low cardiovascular risk menopausal women.

Authors:  Virginia M Miller; Brian D Lahr; Kent R Bailey; Howard N Hodis; Sharon L Mulvagh; Muthuvel Jayachandran
Journal:  Atherosclerosis       Date:  2015-12-28       Impact factor: 5.162

3.  Microparticles in endothelial cell and vascular homeostasis: are they really noxious?

Authors:  Olivier Morel; Florence Toti; Nicolas Morel; Jean-Marie Freyssinet
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

4.  Moderate-intensity exercise reduces activated and apoptotic endothelial microparticles in healthy midlife women.

Authors:  Corinna Serviente; Amy Burnside; Sarah Witkowski
Journal:  J Appl Physiol (1985)       Date:  2018-09-20

5.  Circulating microparticles in patients with coronary heart disease and its correlation with interleukin-6 and C-reactive protein.

Authors:  Ying Cui; Lihui Zheng; Ming Jiang; Ru Jia; Xiao Zhang; Qishan Quan; Guiqin Du; Dongjin Shen; Xiaodan Zhao; Wenying Sun; Hongwei Xu; Lijuan Huang
Journal:  Mol Biol Rep       Date:  2013-11       Impact factor: 2.316

Review 6.  Microvesicles at the crossroads between infection and cardiovascular diseases.

Authors:  Jing Xiong; Virginia M Miller; Yunman Li; Muthuvel Jayachandran
Journal:  J Cardiovasc Pharmacol       Date:  2012-02       Impact factor: 3.105

7.  Congress on women's health Trudy Bush lecture 2014: new insights into sex Hormones and Cardiovascular disease.

Authors:  Virginia M Miller
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

8.  Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).

Authors:  V M Miller; D M Black; E A Brinton; M J Budoff; M I Cedars; H N Hodis; R A Lobo; J E Manson; G R Merriam; F Naftolin; N Santoro; H S Taylor; S M Harman
Journal:  J Cardiovasc Transl Res       Date:  2009-05-22       Impact factor: 4.132

9.  Women's Health Initiative Hormone Therapy Trials: New insights on Cardiovascular Disease from Additional Years of Follow up.

Authors:  Virginia M Miller; Joann E Manson
Journal:  Curr Cardiovasc Risk Rep       Date:  2013-06-01

10.  Aggregation and microparticle production through toll-like receptor 4 activation in platelets from recently menopausal women.

Authors:  Kazunori Hashimoto; Muthuvel Jayachandran; Whyte G Owen; Virginia M Miller
Journal:  J Cardiovasc Pharmacol       Date:  2009-07       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.